First Report Managed Care - Home

Mylan plans to improve access and increase costs savings within the $20 billion antiretroviral marketplace, by launching 2 of its HIV combination treatments—Symfi Lo and Cimduo—at a significant discount compared with other HIV treatments. | Read More
23andMe, maker of direct-to-consumer genetic screening kits, recently received the first ever FDA authorization for a BRCA mutation over the-counter screening test. | Read More
After weeks of deal-making, the Republican-controlled Congress approved a $1.3 trillion spending bill that does not include money for ACA market stabilization. | Read More
Two biosimilar forms of Rituxan Hycela (rituximab; Roche), biologics used for treating blood cancer, have dominated the market in the United Kingdom within a year of launching—while neither have even been approved for sale in the United States. | Read More